[18F]-APN-1607

DRUG2 trials

Sponsors

JYAMS PET Research & Development Limited

Conditions

Alzheimer's DiseaseSubjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

Phase 3

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

RecruitingNCT07422857

JYAMS PET Research & Development LimitedSubjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

Start: 2026-01-22End: 2027-02-01Target: 316Updated: 2026-02-20

Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

RecruitingNCT07752784

JYAMS PET Research & Development LimitedAlzheimer's Disease

Start: 2026-08-15End: 2027-08-15Target: 12Updated: 2026-08-17